RudaCure has establecido RudaCure U.S.A. Inc. to expand its presence in the United States.
The U.S. subsidiaria se espera que serve as the sede central for future U.S. ensayo clínicos of RCI002, as well as to attract U.S. local inversións under the Bio iCORE proyecto, develop U.S. grants, and act as a forward base for open innovación.
The U.S. address is 40W. 37th St. Suite 801, New York, NY 10018.